title: T cells for suicide gene therapy: activation, functionality and clinical relevance.
abstract: In order to control graft-versus-host disease after donor lymphocyte infusion, T cells can be retrovirally transduced with a suicide gene. However, the immune competence of activated T cells appears compromised, responsible for reduced alloreactivity. The present study compared different activation protocols using soluble or bead-coupled antibodies regarding T-cell subtype expansion capacity and functionality. T cells were purified on a laboratory and clinical scale using both CD3 and CD4/CD8 antibodies for selection, leading to a mean purity of 96%. Transductions were performed with a GMP-grade CD34/HSV-TK vector. Activation with soluble CD3/CD28-antibodies +1000 U/ml IL-2 induced a 50-fold expansion of T cells over 14 days, whereas T cells activated with bead-coupled antibodies only expanded 2-4-fold restricted to the first week. Apart from using soluble antibodies, proliferation was highly IL-2 dependent. Expansion of CMV-specific T cells coincided with the expansion of whole CD3(+) cells. Soluble antibodies and higher IL-2 concentrations preferentially stimulated CD8(+) T cells, while bead-coupled antibodies +20 U/ml IL-2 preserved the CD4/CD8 ratio. Irrespective of the activation protocol, there was a shift from a naive to memory phenotype. When activated with soluble antibodies, mainly CD8(+) T cells were transduced. Furthermore, Th1/Th2 cytokine secretion was reduced. In contrast, CD4(+)/CD8(+) T cells activated with bead-coupled antibodies were rather homogenously transduced and cytokine secretion did not appear to be affected.
authors.affiliation: Centre of Pediatric Hematology and Oncology, J.W. Goethe-University, Theodor Stern Kai 7, 60596 Frankfurt, Germany.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Hollatz
authors.forename: M
authors.initials: M
authors.lastname: Grez
authors.forename: S
authors.initials: S
authors.lastname: Mastaglio
authors.forename: R
authors.initials: R
authors.lastname: Quaritsch
authors.forename: S
authors.initials: S
authors.lastname: Huenecke
authors.forename: F
authors.initials: F
authors.lastname: Ciceri
authors.forename: C
authors.initials: C
authors.lastname: Bonini
authors.forename: R
authors.initials: R
authors.lastname: Esser
authors.forename: T
authors.initials: T
authors.lastname: Klingebiel
authors.forename: J
authors.initials: J
authors.lastname: Kreuter
authors.forename: U
authors.initials: U
authors.lastname: Koehl
mesh_terms: D018106:CD28 Antigens / Q000276:immunology / Q000378:metabolism; D017252:CD3 Complex / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology / Q000378:metabolism*; D008213:Lymphocyte Activation; D016176:T-Lymphocyte Subsets / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*; D014161:Transduction, Genetic / Q000379:methods*
chemical_list: D018106:CD28 Antigens; D017252:CD3 Complex; D016207:Cytokines; D007376:Interleukin-2